Anti-Idiotypic Antibodies

Green Mountain Antibodies specializes in the production of custom anti-idiotypic (anti-ID) antibodies. We support our customers through discovery, pre-clinical and clinical trials.

Customized anti-idiotypic antibody services

GMAb offers monoclonal antibody development to support custom anti-idiotypic antibody campaigns. We approach monoclonal antibody development by immunizing mice or rats with the therapeutic, or purified antibody (or Fab fragment), and screening against the antigen IgG and an irrelevant IgG as a control. Antibodies with the correct specificity, known as anti-idiotypic antibodies (anti-ID), are expanded. Specificity to the variable region is confirmed using the ligand recognized by the antigen antibody.  Knowing the purpose and final assay goals will assist in identifying hybridoma screening strategies. Immunogenicity assays, including PD assays, PK assays, and ADA assays are common applications.


Types of anti-idiotypic antibodies

  • TYPE I: Antibody detects free antibody drug. Antibodies used in a neutralizing assay (nAb Assay)
  • TYPE II: Antibody detects bound, partially bound and free drug antibodies; not inhibitory
  • TYPE III: Antibody detects bound antibody drug only. Measure the antibody drug/target complex


Support Through Pre-clinical & Clinical Trials

Over the last 10 years the introduction of immune therapies, which includes immuno-oncology, has greatly increased the need for custom anti-idiotypic antibody production. These therapies have changed the landscape of clinical trials and the drug pipeline. Over 500 monoclonal antibody targets have been investigated. The timeline from concept to clinic is now only one year. One out of 4 monoclonal therapies are receiving FDA approval, where one out of 8 small molecules receive the same result.


Monoclonal Lead Generation and Discovery

In addition to anti-idiotypic projects, GMAb assists translational science groups in creating tool antibodies and monoclonals against biomarkers for discovery lead generation. Such projects require increased diversity, where maximizing the number of antibody candidates is very important. Our strategy is to cast a wide net and incorporate multiple strains of animals, targeted immunization protocols, such as RIMMS, and complex ELISA assay development.

Not sure what you need?

Our expert team will guide you every step of the way.

Contact Us